Department of Women and Children's Health Care, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
JAMA Netw Open. 2021 May 3;4(5):e218401. doi: 10.1001/jamanetworkopen.2021.8401.
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide. Within-country studies have reported racial differences in the presentation and outcome, but little is known about differences between countries.
To compare preeclampsia prevalence, risk factors, and pregnancy outcomes between the Swedish and Chinese populations.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study compared deliveries from the Swedish national Medical Birth Register (2007-2012) and the China Labor and Delivery Survey (2015-2016). The Swedish Medical Birth Register records maternal, pregnancy, and neonatal information for nearly all deliveries in Sweden. The China Labor and Delivery Survey was conducted throughout China, and these data were reweighted to enable national comparisons. Participants included 555 446 deliveries from Sweden and 79 243 deliveries from China. Data management and analysis was conducted from November 2018 to August 2020 and revised in February to March 2021.
Maternal characteristics, parity, multiple gestation, chronic and gestational diabetes, cesarean delivery.
Preeclampsia prevalence and risk factors, overall and for mild and severe forms and rates of adverse neonatal outcomes compared with pregnancies with no gestational hypertension.
The 555 446 Swedish pregnancies and 79 243 Chinese pregnancies had mean (SD) maternal age of 30.9 (5.3) years and 28.6 (4.6) years, respectively. The overall prevalence of preeclampsia was similar in Sweden and China, 16 068 (2.9%) and 1803 (2.3%), respectively, but with 5222 cases (32.5%) considered severe in Sweden and 1228 cases (68.1%) considered severe in China. Obesity (defined as BMI ≥28 in China and BMI ≥30 in Sweden) was a stronger risk factor in China compared with Sweden (China: odds ratio [OR], 5.12; 95% CI, 3.82-6.86; Sweden: OR, 3.49; 95% CI, 3.31-3.67). Nulliparity had a much stronger association with severe preeclampsia in Sweden compared with China (Sweden: OR, 3.91; 95% CI, 3.65-4.18; China: OR, 1.65; 95% CI, 1.20-2.25). The overall stillbirth rate for singleton in China was more than 3-fold higher than in Sweden (846/77 512[1.1%] vs 1753/547 219 [0.3%], P < .001), and 10-fold higher among women with preeclampsia (66/1652 [4.6%] vs 60/14 499[0.4%], P < .001).
In this study, the prevalence rates of preeclampsia in Sweden and China were similar, but women in China had more severe disease and worse pregnancy outcomes than women in Sweden. The associations of obesity and nulliparity with preeclampsia suggest a role for lifestyle and health care factors but may reflect some differences in pathophysiology. These findings have relevance for current efforts to identify high-risk pregnancies and early serum markers because the value of risk prediction models and biomarkers may be population specific.
子痫前期是全球孕产妇和围产儿发病率和死亡率的主要原因。国内研究报告称,种族之间在表现和结局方面存在差异,但对国家之间的差异知之甚少。
比较瑞典和中国人群的子痫前期患病率、危险因素和妊娠结局。
设计、地点和参与者:本横断面研究比较了瑞典国家医疗出生登记处(2007-2012 年)和中国分娩调查(2015-2016 年)的数据。瑞典国家医疗出生登记处记录了瑞典几乎所有分娩的产妇、妊娠和新生儿信息。中国分娩调查在全国范围内进行,这些数据经过重新加权,以实现全国比较。参与者包括瑞典的 555446 次分娩和中国的 79243 次分娩。数据管理和分析于 2018 年 11 月至 2020 年 8 月进行,并于 2021 年 2 月至 3 月进行修订。
产妇特征、产次、多胎妊娠、慢性和妊娠期糖尿病、剖宫产。
比较了无妊娠期高血压的妊娠与轻度和重度子痫前期的总体患病率和危险因素,以及不良新生儿结局的发生率。
555446 例瑞典妊娠和 79243 例中国妊娠的产妇平均(SD)年龄分别为 30.9(5.3)岁和 28.6(4.6)岁。瑞典和中国的子痫前期总患病率相似,分别为 16068(2.9%)和 1803(2.3%),但瑞典有 5222 例(32.5%)被认为是重度,中国有 1228 例(68.1%)被认为是重度。肥胖(在中国定义为 BMI≥28,在瑞典定义为 BMI≥30)是中国比瑞典更强的危险因素(中国:比值比[OR],5.12;95%置信区间[CI],3.82-6.86;瑞典:OR,3.49;95% CI,3.31-3.67)。与中国相比,初产妇与重度子痫前期的相关性在瑞典要强得多(瑞典:OR,3.91;95% CI,3.65-4.18;中国:OR,1.65;95% CI,1.20-2.25)。中国单胎的死胎率比瑞典高 3 倍以上(846/77512[1.1%]比 1753/547219[0.3%],P<0.001),子痫前期患者的死胎率高 10 倍(66/1652[4.6%]比 60/14499[0.4%],P<0.001)。
在这项研究中,瑞典和中国的子痫前期患病率相似,但中国女性的疾病更严重,妊娠结局更差。肥胖和初产妇与子痫前期的相关性表明生活方式和医疗保健因素起作用,但可能反映了一些病理生理学方面的差异。这些发现与目前识别高危妊娠和早期血清标志物的努力有关,因为风险预测模型和生物标志物的价值可能因人群而异。